Description
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
Overview
Clone REA301 recognizes the mouse CD101 antigen, a type I transmembrane glycoprotein also known as immunoglobulin superfamily member 2 (IgSF2) or V7. CD101 is expressed on monocytes, granulocytes, dendritic cells (DCs), and activated T cells. In humans CD101 inhibits the proliferative response of T cells to allogeneic cells or immobilized anti-CD3 antibody, suggesting that engagement of CD101 can antagonize TCR/CD3-mediated lymphocyte activation. Moreover, human peripheral CD8+ T cells that express CD101 and CD103 display suppressive function after activation with intraepithelial cells or placental trophoblasts. In addition to its role on T cells, triggering CD101 on human cutaneous DCs inhibits T cell proliferation via interleukin 10 (IL-10) production, suggesting that the CD101 molecule may be involved in tolerance induction. Studies in mice showed that cell surface expression of CD101 is highly correlated with functional suppressor activity within CD4+CD25+ T regulatory cells both in vitro and in vivo.
Additional information: Clone REA301 displays negligible binding to Fc receptors.
